Antibodies for bioanalysis and drug monitoring of cemiplimab

Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the monoclonal antibody drug cemiplimab (Libtayo) using our range of ready-made antibodies.

  • Recombinant, inhibitory antibodies specific to cemiplimab
  • TrailBlazer Antibody enabling site-directed conjugation and format switching
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Stringent quality control for batch-to-batch consistency

Table 1. Antibodies Specific to Cemiplimab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Cemiplimab

Inhibitory

Type 1

TZA006

AbD41947ad

Fab-F-Spy2-H1

2

PK bridging ELISA

Order TZA006

HCA367

AbD41949ia

Human IgG1

6

ADA control

Order HCA367

HCA368

AbD41947ia

Human IgG1

2

PK bridging ELISA

ADA control

Order HCA368

HCA369

AbD41951ia

Human IgG1

9

ADA control

Order HCA369

* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.


Anti-Cemiplimab Inhibitory Antibodies (Type 1)

Type 1 anti-cemiplimab antibodies inhibit the binding of the drug cemiplimab to its target, human programmed death receptor-1 (PD-1). They are ideal for development of a PK bridging ELISA to measure free drug. In fully human IgG1 format, they are available in three affinities and are suitable as a surrogate positive control or calibrator for an ADA assay.

TrailBlazer Antibody, clone AbD41947ad (TZA006), has a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction, that simply requires mixing at room temperature, this antibody can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Cemiplimab PK bridging ELISA using antibodies TZA006 and HCA368.

Fig. 1. Cemiplimab PK bridging ELISA using antibodies TZA006 and HCA368.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


ADA Bridging ELISA


Fig. 2. Cemiplimab ADA bridging ELISA using antibody HCA367, HCA368, or HCA369.

Fig. 2. Cemiplimab ADA bridging ELISA using antibody HCA367, HCA368, or HCA369.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.